15 Oct 2026: Kindeva’s global health security division, Meridian Medical Technologies, LLC, has been awarded a $226 million contract to provide life-saving Antidote Treatment Nerve Agent Autoinjectors (ATNAA) for Defense Logistics Agency customers. With the potential of delivering over 3 million units from Kindeva’s autoinjector assembly center, the contract is set to support the U.S. warfighter against potential chemical threats.
In addition to supplying equipment and medical products, the DLA oversees the procurement and distribution of critical resources across the Army, Navy, Air Force, Marine Corps and other federal agencies. Under its contract with Kindeva, the agency will support the safe manufacture and delivery of ATNAA.
Kindeva also produces DuoDote®, the civilian version of ATNAA. DuoDote® is provided to other U.S. government (USG) agencies, first responders and 30+ allied nations in preparation for domestic and international mass casualty events. Together, ATNAA and DuoDote®, are the only FDA approved dual chamber autoinjectors for nerve agent antidotes designed to administer atropine and pralidoxime chloride for the treatment of poisoning caused by organophosphorus nerve agents and organophosphorus insecticides.
“We are thrilled to announce our new partnership with the DLA as Kindeva continues to support the U.S. government in addressing evolving global security threats,” said David Stevens, CEO of Kindeva.
He continued: “Following the recent visit from the DLA to our St. Louis facility, we were proud to showcase our proven expertise in fill finish and highlight how our team is delivering critical medical countermeasures (MCM). This contract reflects Kindeva’s longstanding dedication to manufacturing high-quality, reliable treatments that help protect military personnel and civilian communities alike.”
“Successful execution of this contract is the result of over a year’s worth of close collaboration and honest communication with the DLA Team. Kindeva is excited to continue supporting the warfighter as the sole-source of this essential MCM,” said Tara Butler, Director, Government Contracts, Global Health Security
Kindeva will manufacture ATNAA auto injectors at its St. Louis, Missouri campus. The St. Louis campus is a part of a network in the region, strategically located to service pharmaceutical and biotech customers. The newest addition in Bridgeton specializes in fill finish production and was recently recognized as an ISPE “Facility of the Future” finalist in 2025.
Find out more about Kindeva’s services here.
Related news
Explore more of our latest news and announcements, where the demands of today meet the possibilities of tomorrow.
Kindeva Opens New UK HQ and Manufacturing Site for the Development of Next-Generation Propellants
SEPT 18th 2025: Kindeva, a global CDMO and drug delivery expert, has officially opened its new UK headquarters at Charnwood Campus Science Innovation and Technology Park, Loughborough. The facility represents a significant expansion in Kindeva’s MDI services and will develop and test next-generation propellants (NGP) as the industry prepares to move to more environmentally friendly […]
Learn More
Kindeva Drug Delivery awarded up to $129 million to supply DuoDote® autoinjectors to the Strategic National Stockpile
ST. LOUIS, Mo. and WOODBURY, Minn: 16th Jan 2025 (Business Wire) – Kindeva Drug Delivery’s global health security division, Meridian Medical Technologies, LLC, secured a contract valued at up to $129 million to supply DuoDote®, a chemical nerve agent antidote autoinjector, to the Strategic National Stockpile (SNS), managed by the Administration for Strategic Preparedness and […]
Learn MoreKindeva Drug Delivery and Emervax partner to bring game changing vaccine administration to patients
Woodbury, Minnesota and Houston, Texas – JAN 09, 2025: Kindeva Drug Delivery, a global CDMO and drug delivery expert, and Emervax, a developer of a proprietary circular RNA-based vaccine platform (emxRNATM), today announced an exclusive partnership to co-develop a game-changing solution for the administration of vaccines targeting a variety of emerging viruses. Kindeva has granted […]
Learn MoreKindeva Global Health Security donates ATNAA to Ukraine through the European Commission’s rescEU and Governmental Strategic Reserves Agency (RARS)
WOODBURY, Minn. and ST. LOUIS, Mo.; May 29, 2024 (Business Wire) – Kindeva Drug Delivery (Kindeva), a leading global health security provider of CBRN medical countermeasures, announced that it donated a supply of autoinjectors — specifically an antidotal treatment for chemical nerve agents — to Ukraine through the rescEU reserve of the EU Civil Protection […]
Learn MoreKindeva Drug Delivery acquires Summit Biosciences, a specialized Nasal Drug Development and Manufacturing organization
WOODBURY, Minn., ST. LOUIS, Mo., LEXINGTON, Ky.; Jan. 18, 2024 (Business Wire) Kindeva Drug Delivery (“Kindeva”), a global leader in drug-device combination products, announced today that it has acquired Summit Biosciences Inc. (“Summit”), an intranasal drug-delivery contract development and manufacturing organization (CDMO), from its founding family shareholders. Established in 2009, Summit has an extensive track […]
Learn MoreNutriband signs Commercial Development and Clinical Supply Agreement with Kindeva Drug Delivery for Aversa™ Fentanyl, an abuse deterrent fentanyl patch
ORLANDO, FL / ACCESSWIRE / January 5, 2024 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a company engaged in the development of transdermal pharmaceutical products, today announced it has signed a commercial development and clinical supply agreement for their lead product, Aversa™ Fentanyl, with their partner, Kindeva Drug Delivery, a leading global contract development and manufacturing organization (CDMO) […]
Learn MoreKindeva Drug Delivery and Orbia Fluorinated Solutions (Koura) announce collaboration for Low GWP Propellant Conversion
WOODBURY, Minn. and St. LOUIS, Mo. and BOSTON; Dec. 5, 2023 – Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, and Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) Fluorinated Solutions business (Koura®), a global leader in the development, manufacture, and supply of fluoroproducts and […]
Learn MoreMeridian Medical Technologies, Kindeva Drug Delivery’s Global Health Security Division, awarded contract to supply DuoDote®
ST. LOUIS, Mo. and WOODBURY, Minn.; Nov. 14, 2023 (Business Wire) – Meridian Medical Technologies, LLC (Meridian), a division of Kindeva Drug Delivery (Kindeva), has been awarded a $9.9M contract to supply DuoDote® to the Administration for Strategic Preparedness and Response (ASPR) within the United States (U.S.) Department of Health and Human Services. Meridian is […]
Learn MoreMeridian Medical Technologies, LLC, and the European Commission’s DG HERA sign agreement for 13 countries from the EEA to purchase Tecovirimat SIGA
ST. LOUIS, Mo. and WOODBURY, Minn.; Oct. 23, 2023 (Business Wire) – Meridian Medical Technologies, LLC (Meridian), a global health security leader in providing medical countermeasures, today announced a framework contract under the Joint Procurement Agreement (JPA) was signed between Meridian and the European Commission’s Directorates-General (DG) HERA (Health Emergency Preparedness and Response Authority). As […]
Learn MoreManufacturing More Tomorrows™
Partner with us and benefit from a team with technical expertise and a passion for purpose. As a true partner, strategically minded and dedicated to your lasting legacy, we provide customized solutions tailored to your precise requirements. From development to commercial manufacturing and beyond, our CDMO solutions are designed to help your product progress with purpose.
